At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.
Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.